Impact of Hemodialysis on Efficacies of the Antiplatelet Agents in Coronary Artery Disease Patients Complicated with End‑Stage Renal Disease

Author:

Ye Zekang1,Ullah Inam2,Wang Qin1,Lin Qingxia1,Wu Tianyu1,Yang Mingwen1,Fan Yuansheng1,Dong Zhou1,Wang Tong1,Teng Jianzhen1,Hua Rui1,Tang Yingdan3,Li Yule4,Gong Xiaoxuan1,Yuan Liang1,Li Chunjian1

Affiliation:

1. Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University

2. Department of Neurology, the Fifth Affiliated Hospital of Wenzhou Medical University

3. Department of Biostatistics, School of Public Health, Nanjing Medical University

4. College of Letters and Science, University of Wisconsin-Madison

Abstract

Abstract Background It is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end‑stage renal disease (ESRD). Methods 86 CAD patients complicated with ESRD requiring hemodialysis were consecutively enrolled. After 5-day treatment with aspirin and clopidogrel or ticagrelor, the platelet aggregations induced by arachidonic acid (PLAA) or adenosine diphosphate (PLADP), and the P2Y12 reaction unit (PRU) were measured before and after hemodialysis. The propensity matching score method was adopted to generate a control group with normal renal function from 2439 CAD patients. Results In patients taking aspirin, the PLAA remained unchanged after hemodialysis. In patients taking clopidogrel, the PLADP (37.26 ± 17.04 vs. 31.77 ± 16.09, p = 0.029) and corresponding clopidogrel resistance (CR) rate (23 [48.9%] vs.14 [29.8%], p = 0.022) significantly decreased after hemodialysis, though PRU remained unchanged. Subgroup analysis indicated that PLADP significantly decreased while using polysulfone membrane (36.8 ± 17.9 vs. 31.1 ± 14.5, p = 0.024). In patients taking ticagrelor, PLADP, and PRU remained unchanged after hemodialysis. ESRD patients had higher incidences of aspirin resistance (AR) and CR compared to those with normal renal function (AR: 16.1% vs. 0%, p = 0.001; CR: 48.4% vs. 24.8%, p = 0.024). Conclusion Hemodialysis does not have negative effect on the efficacies of aspirin, clopidogrel and ticagrelor in ESRD patients with CAD. On the contrary, clopidogrel response may be improved while using the polysulfone membrane during hemodialysis. ESRD patients have higher incidences of AR and CR compared with those with normal renal function. Trial registration ClinicalTrials.gov Identifier: NCT03330223.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3